News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment simplification strategies news

Show

From To
Treatment simplification strategies
Dolutegravir Monotherapy for HIV No Longer Recommended

Dolutegravir monotherapy should no longer be used as HIV maintenance therapy, according to Bart J.A. Rijnders, MD, PhD, and Casper Rokx, MD, PhD, both from Erasmus Medical Center, Rotterdam, the Netherlands.

Published
09 January 2019
From
Contagion Live
HIV treatment
Top 10 HIV Clinical Developments of 2018

It's the beginning of the end. Not in some apocalyptic way, but rather in how we think about the prevention and management of HIV.

Published
20 December 2018
From
The Body Pro
Pharmaceutical industry
Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company's first doublet has performed modestly on the market compared to a key rival's three-drug regimen.

Published
12 December 2018
From
BioPharma Dive
Treatment simplification strategies
Dual HIV Regimen Equaled Triple Even After Treatment Failure

A "dual" combination of raltegravir (Isentress) plus boosted protease inhibitor was comparable to triple combination regimens with raltegravir for HIV in treatment-experienced patients, including those with previous treatment failure, in a retrospective study with real-world cohort.

Published
26 November 2018
From
MD Magazine
New and experimental HIV treatments
Tivicay Plus Boosted Prezista Shows Promise as Two-Drug HIV Regimen

However, the regimen appears much less potent for those who aren’t virally suppressed.

Published
16 November 2018
From
Poz
Treatment simplification strategies
Dolutegravir plus darunavir maintains viral suppression without NRTIs

A dual antiretroviral regimen containing dolutegravir (Tivicay) and boosted darunavir (Prezista) maintains viral suppression in most people who switch from a suppressive three-drug regimen, according to an observational

Published
06 November 2018
By
Liz Highleyman
Treatment simplification strategies
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects

Antiretroviral treatment with a boosted protease inhibitor and one other drug is just as effective as three-drug antiretroviral therapy containing a boosted protease inhibitor but results in

Published
30 October 2018
By
Keith Alcorn
Treatment simplification strategies
Studies confirm long-term effectiveness of new single-tablet regimens

The newest once-daily, all-in-one HIV combination pills can maintain undetectable viral load for two years and counting, according to a set of studies presented at IDWeek 2018

Published
18 October 2018
By
Liz Highleyman
New and experimental HIV treatments
Dual-antibody combination therapy produces three to seven months of viral suppression without pills

A group of researchers have for the first time used infusions of antibodies to produce prolonged suppression of HIV viral load without antiretroviral therapy (ART) in the

Published
08 October 2018
By
Gus Cairns
New and experimental HIV treatments
ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV

ViiV Healthcare today announced submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.

Published
16 September 2018
From
ViiV press release
← Prev12345...7Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.